Lysosomotropic drug delivery is not a novel concept : it is a decade since De Duve and colleagues (De Duve et al., 1974) discussed the potential of drug delivery to the lysosomal compartment of the cell. Drugs can be directed to lysosomes via two distinctly different routes. Permeant low molecular weight compounds can cross cellular and intracellular membranes, thus gaining access to the lysosomal interior, and various approaches have been employed to ensure trapping and concentration of such compounds in the lysosome. For example Goldman and colleagues (Goldman, 1976) have shown that methyl esters of amino acids and dipeptides diffuse passively into lysosomes but, following hydrolysis of the methyl group by lysosomal esterases, the more polar free amino acid molecules cannot readily pass back across the lysosomal membrane and hence they accumulate to high concentrations. Similarly weakly basic compounds (whose pK is between 5 and 9) accumulate in lysosomes, since they are protonated inside but not outside the lysosome (De Duve et al., 1974) , and thus their exit from the lysosome is hindered. Recently Firestone and colleagues (Firestone et a / . , 1979; Firestone e t a / . , 1982a,b; Miller et al., 1983) have synthesized and investigated the cytotoxic action of lysosomotropic detergents. By attaching amines of intermediate pK, such as imidazole or morpholine, to long hydrocarbon chains they produced detergents that accumulated in lysosomes, altered membrane permeability and later caused direct cytotoxic effects. Although low molecular weight compounds can very effectively be directed into lysosomes, the major disadvantage of their use for therapeutic ; to lysosomes purposes must be the difficulty of achieving selectivity in action, as all lysosome-containing cells will be affected.
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Lysosomes can be reached via an alternative route, namely the cellular uptake mechanism of endocytosis. Many investigators have attached pharmacological agents to carrier macromolecules (reviewed in Gregoriadis, 1979; Gregoriadis et al., 1982) or entrapped them within vesicular carriers (reviewed in Bundgaard et al., 1982; Poste, 1983) with the aim of limiting drug capture to endocytosis and hence affecting body distribution. During recent years we have turned our attention to the investigation of soluble synthetic polymers as drug carriers Duncan er al., 1983a; Duncan & Lloyd, 1984; KopeEek, 1984) . Polymers have certain advantages over naturally occurring macromolecules as drug carriers, the most important being the versatility of polymer chemistry which enables them to be tailor-made to fulfil specific biological functions. Materials'can be synthesized to include appropriate drugpolymer linkages and targeting residues, the optimum molecular weight of the carrier can be chosen, and polymers can be selected that are non-toxic and non-immunogenic (Duncan & KopeEek, 1984) .
Design of polymer-drug linkages for lysosomal cleavage
In order to achieve efficient cell-specific targeting of a drug conjugate, it is essential that the conjugate be stable during transport to the target tissue. We have shown that N-(2-hydroxypropyl)methacrylamide copolymers can be synthesized to contain peptidyl side-chains that are not hydrolysed on incubation with rat plasma or serum (P. Rejmanovi, J. Kopezek, R. Duncan & J. B. Lloyd, unpublished work). Likewise we have demonstrated that these potential drug-polymer linkages can be designed so that their amino acid composition renders them susceptible to cleavage by lysosomal proteinases (Duncan et al., 1980 (Duncan et al., , 1982a . As hydrolysis was inhibited by leupeptin and BIOCHEMICAL SOCIETY TRANSACTIONS stimulated by the presence of reduced glutathione, it was apparent that the Iywsomal thiol-proteinases were important in side-chain cleavage. Incubation of methacrylamidebased copolymers with isolated bovine spleen cathepsins B, H and L subsequently showed all three enzymes are capable of cleaving a terminal p-nitroaniline residue from their peptidyl side-chains (Rejmanova et al., 1983; KopeEek, 1984) , but cathepsin B was the most important enzyme for cleavage of terminal residues from these peptidyl sidechains.
Experiments carried out with model polymeric carriers incubated with isolated enzymes indicate that lysosomal hydrolytic capacity may be used to produce efficient intracellular liberation of drugs. Copolymers of N-(Zhydroxypropy1)methacylamide bearing side-chains containing tyrosine, e.g. P-Gly-Gly-Tyr-NAP, were radiolabelled with 251 and their pinocytosis and intracellular degradation by rat visceral yolk sacs monitored in uitro (Duncan et al., 1981a) . It was demonstrated that following pinocytic capture copolymer side-chains were hydrolysed intralysosomally, in a leupeptin-dependent manner and the rate of side-chain cleavage was clearly related to amino acid composition. The drug analogue [ *51]iodotyrosine released from the polymer subsequently escaped from the tissue.
Pinocytosis of polymeric drug carriers
Ideally a targetable drug carrier should be captured by receptor-mediated absorptive pinocytosis at the target cell and by fluid-phase pinocytosis at all other cell types. This would achieve optimal drug delivery at the required site of action and minimize deposition elsewhere. We have shown that N-(2-hydroxypropyl)methacrylamide copolymers are captured by the rat visceral yolk sac in uitro (Duncan et al., 198 la) and cleared from the blood circulation (Cartlidge et al., 1984; Duncan & Lloyd, 1984) at rates compatible with capture by fluid-phase pinocytic uptake. This allows the maximum opportunity for polymer modification to enhance cell-specific capture.
Certain non-specific features including charge and hydrophobicity govern the interaction of macromolecular substrates with the cell surface, and the factors that influence substrate selection and processing in endocytosis are discussed elsewhere (Lloyd et al., 1984) . Of particular importance here is the effect of substrate size on its pinocytic capture. We have shown that the capture of both N-(2-hydroxypropy1)methacrylamide copolymers and poly(viny1pyr-rolidone) by rat visceral yolk sacs depends on their mean molecular weights (Duncan et al., 1981b; Cartlidge et al., 1982 ) the highest molecular weight fractions being excluded from the newly forming pinosomes. Obviously a potential polymeric drug carrier must be sufficiently small to gain access to pinocytic vesicles at the target cells, and the failure of vesicular carriers, such as liposomes, to meet this requirement has severely limited their usefulness (Poste, 1983) . High levels of substitution of molecules that do not normally interact with the plasma membrane can lead to enhanced affinities for cell surfaces if the substituent groups are hydrophobic (Duncan et al., 19826, 1984) or cationic (Pratten et al., 1982) . A drug carrier must therefore not be overloaded with drug residues if they will alter substantially the pinocytic properties of the conjugate.
Over the last decade many cell-specific recognition systems have been described (reviewed in Cuatracasas & Roth, 1983; Kleinzeller & Martin, 1983) including receptors for or2-macroglobulin, epidermal growth factor, low-density lipoprotein, insulin, transferrin, lysosomal enzymes and asialoglycoproteins. Attempts are currently being made to utilize these systems for cell-specific targeting of drug conjugates. We have already demonstrated that incorporation of galactosamine into N-(2-hydroxypropyl)methacrylamide copolymers and soluble cross-linked copolymers (Duncan et al., 1983c; Cartlidge et al., 1984) dramatically increases their rate of blood clearance and their rate of capture by liver hepatocytes. This observation is compatible with the known galactose receptor present on the hepatocyte surface.
Fate of synthetic polymers in the body
The N-(2-hydroxypropyl)methacrylamide copolymers described in these studies are not biodegradable and so could potentially accumulate in the body with possible undesirable side-effects. However, N 4 2 -hydroxypropy1)methacrylamide was originally synthesized as a plasma expander and is well tolerated by the body (KopeEek ef al., 1973) . Recent studies have confirmed that N-(Zhydroxypropy1)methacrylamide copolymers are either non-immunogenic or very poorly immunogenic and these observations confirm their potential as drug carriers (Rihova et al., 1983 (Rihova et al., ,1984 . To aid the elimination of the methacrylamide copolymers from the body, soluble cross-linked polymers have been prepared whose main chains are crosslinked by diamine-linked peptide sequences. Preliminary experiments in vim have shown that, after intravenous administration and cleavage of the peptidyl cross-links, lower molecular weight polymer chains are_ released which are eventually excreted in the urine (Kopecek et al., 1981) .
Summary
We have demonstrated that soluble synthetic polymers can be tailor-made to include the principal features of a targetable drug delivery system : drug-carrier linkages that display controlled degradability and determinants to allow direction of conjugate to a predefined cell type. Further experiments are currently in progress to explore the possibilities of targeting to cells other than hepatocytes.
